Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 12Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 18Cholangiocarcinoma 3Thyroid Neoplasms 2Recurrence 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Coitus 1Carcinoma, Renal Cell 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Liquid Biopsy 4Blood Specimen Collection 4Gemcitabine 3pembrolizumab 2Immunohistochemistry 2Cisplatin 2Capecitabine 2Base Sequence 2130-nm albumin-bound paclitaxel 2tislelizumab 1taxane 1lenvatinib 1irinotecan sucrosofate 1gemcitabine-oxaliplatin regimen 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Standard of Care 1S 1 (combination) 1Polymerase Chain Reaction 1Platinum Compounds 1Oxaliplatin 1Nivolumab 1Microscopy, Confocal 1Methylation 1Mass Spectrometry 1Leucovorin 1Irinotecan 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Biliary Tract Neoplasms × lenvatinib × Clear all
NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

CHA University

Recruiting
100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡